Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures

PHASE3CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Epilepsies, Partial
Interventions
DRUG

Pregabalin

Orally-administered pregabalin

Trial Locations (18)

14222

Women and Children's Hospital of Buffalo, Buffalo

27710

Duke University Medical Center, Durham

32561

Child Neurology Center of Northwest Florida, Gulf Breeze

33603

The Office of Sergio J Jacinto, MD, Tampa

33609

Pediatric Epilepsy & Neurology Specialists, Tampa

36604

University of South Alabama, Mobile

36693

University of South Alabama Department of Neurology, Mobile

44280

Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara

65804

St. John's Clinic, Springfield

St. John's Hospital, Springfield

72205

Clinical Study Centers, L. L. C., Little Rock

72401

The Children's Clinica of Jonesboro, P.A, Jonesboro

77030

Baylor College of Medicine - Texas Children's Hospital, Houston

Texas Children's Hospital, Houston

78258

Road Runner Research, Ltd., San Antonio

85016

Phoenix Children's Hospital, Phoenix

94143

UCSF Neurology Clinic, San Francisco

120-752

Yonsei University College of Medicine Severance Hospital / Department of Pediatric Neurology, Seoul

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00448916 - Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures | Biotech Hunter | Biotech Hunter